NEW YORK, December 29, 2025, 17:45 ET — After-hours
Shares of Eli Lilly and Company (LLY) were up 0.2% at $1,078.73 in after-hours trading on Monday. The stock traded between $1,074.80 and $1,085.12 and about 1.64 million shares had changed hands.
The modest move masked a bigger debate underway in the obesity-drug trade: pricing and access. Investors are watching whether Lilly can widen uptake without giving away too much margin.
Pills sit at the center of that calculus because they may lower barriers for patients who avoid injections. A shift toward out-of-pocket buying also changes who sets the rules — insurers, employers and government programs, or consumers.
Wall Street ended lower on Monday as heavyweight technology stocks retreated from last week’s gains, Reuters reported. The S&P 500 fell 0.35% and the Nasdaq lost 0.5%. Minutes from the Federal Reserve’s prior meeting and weekly jobless claims are among the next macro signposts.
Reuters reported that Lilly and rival Novo Nordisk are leaning into telehealth — online services that connect patients with prescribers — and direct-to-consumer channels as they prepare pill versions of blockbuster GLP-1 drugs, which mimic gut hormones to curb appetite and help control blood sugar. Both plan starter doses of their weight-loss pills at $149 a month for U.S. cash-paying customers, and Lilly has said repeat purchasers would pay no more than $399; Lilly’s oral candidate orforglipron is under regulatory review. Digital health firm Welldoc has partnered with Lilly on an app for medication reminders and dose tracking, and CEO Dave Ricks said, “I can charge less and get it to more people at scale,” while IQVIA data cited by Reuters put cash-pay at about 30% of Zepbound prescriptions versus roughly 10% for Wegovy. Reuters
Pricing pressure also showed up abroad. Novo Nordisk said it is adjusting Wegovy prices in China after local media reported sharp cuts for two high-dose packs in some provinces, as the company braces for tougher competition when semaglutide’s patent expires there in 2026.
A Form 4 filing — the SEC report used to disclose insider transactions — showed Lilly Endowment Inc., a director and more than 10% owner, sold 2,629 shares on Dec. 24 at a weighted average price of $1,085.173. The endowment still held 92,194,109 shares, the filing showed.
The disclosed sale was small relative to the size of that stake and did not change the ownership picture. Traders tend to focus more on patterns than one-off transactions.
For valuation, investors are still treating obesity drugs as the stock’s key swing factor. The market is trying to price the trade-off between lower out-of-pocket entry points and the need to sustain profitability as competition broadens.
Monday’s tight range left $1,085 as the near-term reference on the upside and $1,075 as the next support area. Those levels can matter when liquidity thins into year-end and moves get exaggerated.
What investors are watching next is how Lilly frames pill economics versus injections, including any clearer view on pricing for higher doses and the role of telehealth partners in driving adherence. Competitive moves from Novo and smaller entrants are likely to keep the sector’s pricing floor in focus.
For now, Lilly’s shares held up even as the broader market slipped, a reminder that obesity-drug economics remain a market-within-a-market for healthcare investors. Any new signals on cash-pay uptake or the regulatory path for orforglipron could set the tone into the next session.
